News

In case you missed it, this week we had news about rezpegaldesleukin’s fast track designation for AD, bimekizumab’s long-term efficacy for HS, conference recaps of SBS and MOPD, and more.

This week, we feature top articles from our sister publications on FDA approvals, top insights, and new data.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.

The article highlights the immense global burden of atopic dermatitis, the most common chronic inflammatory skin disease, affecting over 200 million individuals worldwide.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Key 2025 tax law changes for dermatologists include expiring TCJA provisions, potential rate adjustments, and new deduction policies under Trump.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

Explore 2025’s dermatology M&A trends, economic shifts, and key investment drivers shaping the industry's future.

The state-of-the-art facilities in California, Georgia, and Texas will expand AMI’s curriculum to providers of all levels.

Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.

Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.

Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.

Uniting all professions should be the goal as it concerns the patient and the access to care.

Catch up on coverage from the 2025 Masters of Pediatric Dermatology held in Miami Beach, Florida.

Trauma-induced melanocyte implantation can lead to subcutaneous melanoma, mimicking melanoma of unknown primary but with distinct diagnostic criteria.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a woman aged 27 years who had eczematous lesions covering more than 20% of her BSA.

New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.

Each treatment saw very mild clinical and dermatologic responses with low levels of patient satisfaction.

This review of the latest dermatologic studies includes insights into endocrine, psychological and nutritional aspects in women with hidradenitis suppurativa; forms of hair loss among individuals with anxiety disorder; and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.

Catch up on coverage from the 2025 South Beach Symposium held in Miami Beach, Florida.